Ideaya Biosciences emerged as a leading small-cap oncology firm following the ASCO 2026 conference. The company is advancing darovasertib to treat uveal melanoma, a rare eye cancer with limited systemic therapy options. The FDA accepted the New Drug Application (NDA) for Real-Time Oncology Review. Ideaya plans to submit the full filing in the second half of 2026.
The Phase 2/3 OptimUM-02 trial met its primary endpoint. Darovasertib combined with crizotinib significantly improved progression-free survival compared to standard treatments.
Ideaya maintains full U.S. commercial rights for the candidate. The company reports a cash runway extending to 2030. Current research is expanding to include new patient populations and disease stages.